BioMarin (BMRN) Q2 Revenue Jumps 16%

BioMarin Pharmaceutical (NASDAQ:BMRN), a biotechnology company focused on therapies for rare genetic conditions, reported results for Q2 2025 on August 4, 2025. GAAP revenue was $825 million, far above expectations of $761.66 million, and non-GAAP Earnings Per Share (EPS) of $1.44 compared to the anticipated $0.82. Both figures marked significant beats against analyst estimates, with non-GAAP EPS and GAAP revenue exceeding consensus, with GAAP revenue up 16% year-over-year and non-GAAP EPS up 50% year-over-year. Management raised full-year 2025 guidance following the strong Q2, including updated targets for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS, driven by robust commercial execution for its leading products VOXZOGO and Enzyme Therapies.

Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.

BioMarin Pharmaceutical develops, manufactures, and markets medicines for people with rare genetic diseases. Its primary focus is on short stature conditions, enzyme deficiencies, and gene therapies for specific inherited disorders. The business is centered around flagship product families like VOXZOGO (an injectable therapy for achondroplasia, the most common form of dwarfism), and multiple Enzyme Therapies targeting specific genetic disorders.

Continue reading

Source Fool.com